Biopharma Dealmaking Quarterly Statistics, Q3 2014
A look at financing, M&A, and alliance activity July–September 2014
Executive Summary
Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.
You may also be interested in...
Cancer Immunotherapy Reaches A Tipping Point
Now that it is clear the immune system can kill cancer, all kinds of companies are obsessed with the idea. Start-ups are tailoring business models to divergent technologies and market dynamics.
A Banner Year For Pharma: M&A Tops 2009 Merger Mania
Fourteen deals have been signed so far in 2014 with an up-front value of $1 billion or more. The standout year for pharma M&A is already more valuable than 2009, the year Pfizer bought Wyeth and Merck acquired Schering-Plough.
Santaris Acquisition By Roche May Help VCs Back New Biotechs In Europe
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.